20
Gynaecologische Tumoren: Internationale richtlijnen en Nieuwe perspectieven in diagnostiek en behandeling Philippe Van Trappen, MD PhD Gynaecologie/Oncologie 1 SYMPOSIUM ONCOLOGIE – 7 JUNI 2008

Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Embed Size (px)

DESCRIPTION

Gynaecologische Tumoren: Internationale richtlijnen en Nieuwe perspectieven in diagnostiek en behandeling. Philippe Van Trappen, MD PhD Gynaecologie/Oncologie. SYMPOSIUM ONCOLOGIE – 7 JUNI 2008. Venous Spread - PowerPoint PPT Presentation

Citation preview

Page 1: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Gynaecologische Tumoren:Internationale richtlijnen en Nieuwe perspectieven indiagnostiek en behandeling

• Philippe Van Trappen, MD PhD• Gynaecologie/Oncologie

1

SYMPOSIUM ONCOLOGIE – 7 JUNI 2008

Page 2: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

2

Venous SpreadThis pathway might account for the

occasional appearance of a low vaginal metastasis; but venous spread is not a common feature of uterine cancer.

Page 3: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

3

Lymphatic Spread The incidence of this (it is much debated)

seems to be somewhere between 10 and 30%. All pelvic nodes, including the internal iliacs, the parametrium, the ovaries, and the vagina may be involved, probably with equal frequency. Lymphatic spread is more likely to occur when the tumour is anaplastic and the uterine wall is deeply invaded.

Page 4: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

4

Tubal Spread Malignant cells can pass along the

tube in the same way that peritoneal spill may occur during menstruation. This may account for isolated ovarian metastases.

Page 5: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

2003-10-27Carcinoma of the

Endometrium 5

Page 6: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

2003-10-27Carcinoma of the

Endometrium 6

Page 7: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Cancers of the Uterine Corpus:Histologic Types

• Carcinoma (94%)Endometrioid (87%)Adenosquamous (4%)Papillary Serous* (3%)Clear Cell* (2%)Mucinous (1%)Other (3%)

• Sarcoma (6%)Carcinosarcoma* (60%)Leiomyosarcoma* (30%)Endometrial Stromal Sarcoma (10%)Adenosarcoma (<1%)

*poor prognosis histology

Page 8: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Endometrial Cancer:Type I/II Concept• Type I

Estrogen RelatedYounger and heavier patientsLow gradeBackground of HyperplasiaPerimenopausalExogenous estrogen

• Type II (~10% of total cases)AggressiveHigh gradeUnfavorable HistologyUnrelated to estrogen stimulationOccurs in older & thinner women

• Familial/genetic (~15% of total cases)Lynch II syndrome/HNPCCFamilial trend

Page 9: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Endometrial Cancer –diagnosis & assessment

• Endometrial biopsy• – outpatient sampling (pipelle aspirate)• – hysteroscopy and curettage• Ultrasound: thickened endometrium/abnormal areas within cavity• or wall of womb• Doppler demonstration of abnormal endometrial vascularity• MRI:• imaging of pelvic/paraaortic lymph nodes and myometrial• invasion• PET-CT• (high sensitivity in detecting distant metastases;• high NPV in predicting LN metastases)• Park et al, 2008, Gynecol Oncol

9

Page 10: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

• IA: Tumor limited to endometrium• IB: Invasion to no more than half the myometrial

thickness.• IC: Invasion to more than half the myometrial

thickness• IIA: Invasion to the mucosa of the cervix.• IIB: Invasion to cervical stroma.

10

Page 11: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

• IIIA: Tumor invades serosa and/or adnexa,and/or positive peritoneal

• cytology• IIIB: Vaginal metastases• IIIC: Metastases to pelvic and/or para-aortic lymph nodes.• IVA Tumor invasion of bladder and/or bowel mucosa.• IVB: Distant metastases including intra-abdominal metastases• and/or inguinal lymph nodes.

11

Page 12: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

• Availability of frozen section to determine the extent of staging procedure.

• Capability of complete surgical staging• Capability of tumor reduction if indicated

Endometrial Cancer: Intra-operative Surgical Principals

Page 13: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Situation % Positive Nodes

G1, inner 1/3 myometrial invasion, no extrauterine disease.

<1%

G2 or G3, inner 1/3 invasion, no extrauterine disease

5-9% Pelvic

4% Aortic

G3 with outer 1/3 invasion, and/or extrauterine disease

20-60% Pelvic

10-30% Aortic

Endometrial Cancer: Nodal Involvement

Page 14: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Endometrial Cancer -1.treatment• Usually surgical• Simple hysterectomy• (Laparoscopic)• and removal of tubes/ovaries only for• well differentiated stage Ia ~ 70%• Stage Ib/Ic, mod/poorly differentiated and poor prognostic types also

require• pelvic/paraaortic lymph node sampling• (FIGO, ACOG)• Uterine Serous Papillary Carcinoma (USPC):• staging like ovarian cancer• Stage II• - radical hysterectomy or simple hysterectomy + RT• Stage III/IV• - cytoreductive surgery (>palliative for bleeding, bladder and• bowel involvement)• Primary radiotherapy is rarely used

2003-10-27Carcinoma of the

Endometrium14

Page 15: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Uterine Cancer: Pre-op Evaluation

•Transvaginal U/S?

•CT Scan?

•MRI?

Page 16: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Endometrial Cancer: Surgical Approach

• TAH-BSO/washings only– Endometrioid*– Grades 1 and < 50% myometrial invasion*– or Grade 2 and no or minimal invasion

and < 2 cm tumor diameter*

*Verified via frozen section

Page 17: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Endometrial Cancer: Surgical Approach

• Complete Surgical Staging*– All Grade 3– Any > 50% myometrial invasion– Any >2 cm tumor diameter– All Serous/clear cell subtype**– Pre operative assessment of advanced

disease (gross cervical or vaginal dz, etc)

*TAH-BSO, washings, lymphadenectomy **omental/peritoneal biopsy

Page 18: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

Laparoscopic Staging:Magrina JF, Weaver AL. Laparoscopic treatment of endometrial cancer:

five-year recurrence and survival rates. Eur J Gynaecol Oncol. 2004;25(4):439-41.

Holub Z, Jabor A, Bartos P, Eim J, Urbanek S, Pivovarnikova R. Laparoscopic surgery for endometrial cancer: long-term results of a multicentric study. Eur J Gynaecol Oncol. 2002;23(4):305-10.

GOG LAP2 Protocol: Randomized study of Total Hysterectomy, BSO and Staging via Laparotomy vs. Laparoscopy- study still open

• Previous studies show:Similar blood lossSame incidence of complicationsLow incidence of conversion of laparoscopy to laparotomyLonger operative times for laparoscopy (160 min vs. 115min)Shorter hospital stay (4 vs 7 days) for laparoscopyNo difference in recurrence risk.

Page 19: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

19

PROGNOSIS OF ENDOMETRIAL CARCINOMA

With the exception of stage 1 tumors of histological grades I and II, the prognosis is less favourable than many gyaecologists believe , with an overall 5 year survival of 70 % approximately . Fortunately over 80% of cases are dagnosed at stage 1 .

Page 20: Philippe Van Trappen, MD PhD Gynaecologie/Oncologie

20

Stage 5 year survival I 85% II 68% III 42% IV 22%